transplantation: a systematic review of randomized trials, Am J Transplant, 2005;5:1748–56.
6. Moore J, Middleton L, Cockwell P, et al., Calcineurin inhibitor sparing with mycophenolate in kidney transplantation: a systematic review and meta-analysis, Transplantation, 2009;87:591–605.
7. Grinyo JM, Cruzado JM, Mycophenolate mofetil and calcineurin-inhibitor reduction: recent progress, Am J Transplant, 2009;9:2447–52.
8. Ekberg H, Tedesco-Silva H, Demirbas A, et al., Reduced exposure to calcineurin inhibitors in renal transplantation, N Engl J Med, 2007;357:2562–75.
9. Ekberg H, Bernasconi C, Tedesco-Silva H, et al., Calcineurin inhibitor minimization in the Symphony study: observational results 3 years after transplantation, Am J Transplant, 2009;9:1876–85.
10. Thervet E, Sirolimus therapy following early cyclosporine withdrawal in transplant patients: mechanisms of action and clinical results, Int J Nanomedicine, 2006;1:269–81.
11. Mota A, Arias M, Taskinen EI, et al., Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years, Am J Transplant, 2004;4:953–61.
12. European Medicines Agency, Summary of Product Characteristics – Rapamune, 2011. Available at: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-
_Product_Information/human/000273/WC500046437.pdf (accessed 18 January 2012).
13. Mulay AV, Cockfield S, Stryker R, et al., Conversion from calcineurin inhibitors to sirolimus for chronic renal allograft dysfunction: a systematic review of the evidence, Transplantation, 2006;82:1153–62.
14. Schena FP, Pascoe MD, Alberu J, et al., Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial, Transplantation, 2009;87:233–42.
15. Flechner SM, Kobashigawa J, Klintmalm G, Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity, Clin Transplant, 2008;22:1–15.
16. Hamdy AF, Bakr MA, Ghoneim MA, Long-term efficacy and safety of a calcineurin inhibitor-free regimen in live-donor renal transplant recipients, J Am Soc Nephrol, 2008;19:1225–32.
17. Flechner SM, Glyda M, Cockfield S, et al., The ORION study: comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients, Am J Transplant, 2011;11:1633–44.
18. Buchler M, Caillard S, Barbier S, et al., Sirolimus versus cyclosporine in kidney recipients receiving thymoglobulin, mycophenolate mofetil and a 6-month course of steroids,
Am J Transplant, 2007;7:2522–31.
19. Guba M, Pratschke J, Hugo C, et al., Renal function, efficacy, and safety of sirolimus and mycophenolate mofetil after short-term calcineurin inhibitor-based quadruple therapy in de novo renal transplant patients: one-year analysis of a randomized multicenter trial, Transplantation, 2010;90:175–83.
20. Budde K, Becker T, Arns W, et al., Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial, Lancet, 2011;377:837–47.
21. Weir MR, Mulgaonkar S, Chan L, et al., Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation: a randomized, controlled Spare-the-Nephron trial, Kidney Int, 2011;79:897–907.
22. Grinyo JM, Campistol JM, Paul J, et al., Pilot randomized study of early tacrolimus withdrawal from a regimen with sirolimus plus tacrolimus in kidney transplantation, Am J Transplant, 2004;4:1308–14.
23. Tedesco Silva H Jr, Cibrik D, Johnston T, et al., Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients, Am J Transplant, 2010;10:1401–13.
24. Vincenti F, Luggen M, T cell costimulation: a rational target in the therapeutic armamentarium for autoimmune diseases and transplantation, Annu Rev Med, 2007;58:347–58.
25. Vincenti F, Larsen C, Durrbach A, et al., Costimulation blockade with belatacept in renal transplantation, N Engl J Med, 2005;353:770–81.
26. Vincenti F, Charpentier B, Vanrenterghem Y, et al., A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study), Am J Transplant, 2010;10:535–46.
27. Durrbach A, Pestana JM, Pearson T, et al., A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study), Am J Transplant, 2010;10:547–57.
28. Vincenti F, Larsen C, Alberu J, et al., Three-year outcomes from BENEFIT: a phase III study of belatacept vs cyclosporine in kidney transplant recipients, Presented at: Annual Congress of the European Renal Association–European Dialysis and Transplant Association (ERA-EDTA), Prague, Czech Republic, 25 June 2011, Abstract SaO043.
29. Durrbach A, Citterio F, Mulloy L, et al., Renal function in patients treated with belatacept- or cyclosporine-based regimens at year 3 in the BENEFIT and BENEFIT-EXT studies, Presented at: Annual Congress of the European Renal Association–European Dialysis and Transplant Association (ERA-EDTA), Prague, Czech Republic, 25 June 2011, Abstract Sa521.
30. Durrbach A, Grinyo J, Vanrenterghem Y, et al., Belatacept compared with cyclosporine in renal allograft recipients of
extended criteria donor kidneys: 3-year outcomes from the phase III BENEFIT-EXT trial, Presented at: Annual Congress of the European Renal Association–European Dialysis and Transplant Association (ERA-EDTA), Prague, Czech Republic, 24 June 2011, Abstract F568.
31. Vincenti F, Larsen CP, Alberu J, et al., Three-Year Outcomes from BENEFIT, a Randomized, Active-Controlled, Parallel-Group Study in Adult Kidney Transplant Recipients, Am J Transplant, 2012;12:210–7.
32. Gill JS, Abichandani R, Kausz AT, Pereira BJ, Mortality after kidney transplant failure: the impact of non-immunologic factors, Kidney Int, 2002;62:1875–83.
33. United States Renal Data System, USRDS 2009 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2009. Available at: www.usrds.org/atlas09.aspx
(accessed 18 January 2012).
34. Aakhus S, Dahl K, Wideroe TE, Cardiovascular morbidity and risk factors in renal transplant patients, Nephrol Dial Transplant, 1999;14:648–54.
35. Vanrenterghem YF, Claes K, Montagnino G, et al., Risk factors for cardiovascular events after successful renal transplantation, Transplantation, 2008;85:209–16.
36. Vanrenterghem Y, Bresnahan B, Campistol J, et al., Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT studies), Transplantation, 2011;91:976–83.
37. Grinyo J, Charpentier B, Pestana JM, et al., An integrated safety profile analysis of belatacept in kidney transplant recipients, Transplantation, 2010;90:1521–7.
38. Traynor K, Kidney transplant drug approved, Am J Health Syst Pharm, 2011;68:1372.
39. Rostaing L, Massari P, Garcia VD, et al., Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase II study, Clin J Am Soc Nephrol, 2011;6:430–9.
40. Grinyo J, Nainan G, Rial Mdel C, et al., Renal function at 2 years in kidney transplant recipients switched from cyclosporine or tacrolimus to belatacept: results from the long-term extension of a phase II study, Presented at: Annual Congress of the European Renal Association–European Dialysis and Transplant Association (ERA-EDTA), Prague, Czech Republic, 24 June 2011, Abstract F567.
41. Ferguson R, Grinyo J, Vincenti F, et al., Immunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients, Am J Transplant, 2011;11:66–76.
| Page 2
| Page 3
| Page 4
| Page 5
| Page 6
| Page 7
| Page 8
| Page 9
| Page 10
| Page 11
| Page 12
| Page 13
| Page 14
| Page 15
| Page 16
| Page 17
| Page 18
| Page 19
| Page 20
| Page 21
| Page 22
| Page 23
| Page 24
| Page 25
| Page 26
| Page 27
| Page 28
| Page 29
| Page 30
| Page 31
| Page 32
| Page 33
| Page 34
| Page 35
| Page 36
| Page 37
| Page 38
| Page 39
| Page 40
| Page 41
| Page 42
| Page 43
| Page 44
| Page 45
| Page 46
| Page 47
| Page 48
| Page 49
| Page 50
| Page 51
| Page 52
| Page 53
| Page 54
| Page 55
| Page 56
| Page 57
| Page 58
| Page 59
| Page 60
| Page 61
| Page 62
| Page 63
| Page 64
| Page 65
| Page 66
| Page 67
| Page 68
| Page 69
| Page 70
| Page 71
| Page 72
| Page 73
| Page 74
| Page 75
| Page 76